

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/10454

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68; A61K 39/395, 49/14; C07K 16/28 US CL : 435/6; 424/143.1, 9.1; 530/388.22 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6; 424/143.1, 9.1; 530/388.22 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN, Medline, Biosis, Embase, WEST																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>MONTGOMERY et al. Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters beta-Tubulin Isotype Expression, Journal of Biological Chemistry, 9 June 2000, Vol. 275, No. 23, pages 17358-17363, see last sentence of the Abstract.</td> <td>1 and 2</td> </tr> <tr> <td>X</td> <td>TOYOSHIMA et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor, Lung Cancer, 2001, Vol. 31, pages 193-202, see page 193, Abstract, page 199-200, the first three paragraphs of the Discussion.</td> <td>1 and 2</td> </tr> <tr> <td>X</td> <td>BORCZUK et al. Non-small-cell lung cancer molecular signatures recapitulate lung development pathways, American Journal of Pathology, 5 November 2003, Vol. 163, No. 5, pages 1949-1960, see page 1954 figure A and page 1958 table 3.</td> <td>1 and 2</td> </tr> <tr> <td>A</td> <td>ZEMBUTSU et al. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839, International Journal of Oncology, 2003, Vol. 23, No. 1, pages 29-39.</td> <td>1 and 2</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	MONTGOMERY et al. Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters beta-Tubulin Isotype Expression, Journal of Biological Chemistry, 9 June 2000, Vol. 275, No. 23, pages 17358-17363, see last sentence of the Abstract.	1 and 2	X	TOYOSHIMA et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor, Lung Cancer, 2001, Vol. 31, pages 193-202, see page 193, Abstract, page 199-200, the first three paragraphs of the Discussion.	1 and 2	X	BORCZUK et al. Non-small-cell lung cancer molecular signatures recapitulate lung development pathways, American Journal of Pathology, 5 November 2003, Vol. 163, No. 5, pages 1949-1960, see page 1954 figure A and page 1958 table 3.	1 and 2	A	ZEMBUTSU et al. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839, International Journal of Oncology, 2003, Vol. 23, No. 1, pages 29-39.	1 and 2			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	MONTGOMERY et al. Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters beta-Tubulin Isotype Expression, Journal of Biological Chemistry, 9 June 2000, Vol. 275, No. 23, pages 17358-17363, see last sentence of the Abstract.	1 and 2																		
X	TOYOSHIMA et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor, Lung Cancer, 2001, Vol. 31, pages 193-202, see page 193, Abstract, page 199-200, the first three paragraphs of the Discussion.	1 and 2																		
X	BORCZUK et al. Non-small-cell lung cancer molecular signatures recapitulate lung development pathways, American Journal of Pathology, 5 November 2003, Vol. 163, No. 5, pages 1949-1960, see page 1954 figure A and page 1958 table 3.	1 and 2																		
A	ZEMBUTSU et al. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839, International Journal of Oncology, 2003, Vol. 23, No. 1, pages 29-39.	1 and 2																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="1"> <thead> <tr> <th colspan="2">Special categories of cited documents:</th> <th></th> </tr> </thead> <tbody> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> </tr> <tr> <td>"B"</td> <td>earlier application or patent published on or after the international filing date</td> <td>"X"</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </tbody> </table>			Special categories of cited documents:			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	"B"	earlier application or patent published on or after the international filing date	"X"	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	"P"	document published prior to the international filing date but later than the priority date claimed	
Special categories of cited documents:																				
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"																		
"B"	earlier application or patent published on or after the international filing date	"X"																		
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"																		
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"																		
"P"	document published prior to the international filing date but later than the priority date claimed																			
Date of the actual completion of the international search 04 October 2005 (04.10.2005)		Date of mailing of the international search report 31 OCT 2005																		
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer David Humphrey <i>J. Roberts for</i> Telephone No. (571) 272-1600																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/10454

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GINOS et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck, Cancer Research, 1 January 2004, Vol. 64, pages 55-63.	1 and 2